Harbour Investments’s Summit Therapeutics SMMT Stock Holding History

Harbour Investments’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88K	Sell	129 -391	-75%	-$6.93K	﹤0.01%	4041
2026 Q1	$9.86K	Buy	520 +463	+812%	+$7.49K	﹤0.01%	3268
2025 Q4	$997	Sell	57 -284	-83%	-$5.34K	﹤0.01%	3454
2025 Q3	$7.04K	Buy	341 +200	+142%	+$4.85K	﹤0.01%	2844
2025 Q2	$3K	Buy	141 +57	+68%	+$1.3K	﹤0.01%	3022
2025 Q1	$1.62K	Buy	+84	New	+$1.69K	﹤0.01%	3135
2023 Q3	–	Sell	-300	Closed	-$753	–	3088
2023 Q2	$753	Hold	300	–	–	﹤0.01%	2743
2023 Q1	$525	Hold	300	–	–	﹤0.01%	2802
2022 Q4	$1.27K	Sell	300 -1,000	-77%	-$1.82K	﹤0.01%	2637
2022 Q3	$1K	Hold	1,300	–	–	﹤0.01%	2655
2022 Q2	$1K	Buy	+1,300	New	+$1.82K	﹤0.01%	2655
2021 Q4	$3K	Hold	1,300	–	–	﹤0.01%	2346
2021 Q3	$7K	Hold	1,300	–	–	﹤0.01%	2849
2021 Q2	$10K	Hold	1,300	–	–	﹤0.01%	2747
2021 Q1	$8K	Buy	+1,300	New	+$8.39K	﹤0.01%	2732

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Harbour Investments's SMMT Position: Q2 2026 in Review

Harbour Investments reduced its Summit Therapeutics (SMMT) stake by 75% in Q2 2026, selling an estimated $6.93K and leaving 129 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Harbour Investments first reported a position in SMMT in Q1 2021 and has held it in 15 quarters since. The position peaked at $10K in Q2 2021. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Harbour Investments held 129 shares of Summit Therapeutics worth $1.88K as of Q2 2026.
Harbour Investments sold 391 Summit Therapeutics shares in Q2 2026, an estimated $6.93K.
Summit Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4041 holding.
Harbour Investments first reported a position in Summit Therapeutics in Q1 2021 and has held it in 15 quarters since.
Harbour Investments's Summit Therapeutics position peaked at $10K in Q2 2021.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.